Lantern Pharma Says Phase 1a Study Of LP-184 Met All Primary Endpoints In Advanced Solid Tumors
(RTTNews) - Lantern Pharma Inc. (LTRN) announced Tuesday that its Phase 1a study evaluating the drug candidate LP-184 in patients with advanced solid tumors, including Glioblastoma Multiforme (GBM), an aggressive form of brain cancer, met all primary endpoints.
The drug showed a robust safety profile with minimal dose-limiting toxicities and early signs of antitumor activity across multiple tumor types.
Leveraging its RADR AI platform, Lantern Pharma is now advancing LP-184 into targeted Phase 1b and Phase 2 studies.
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.